Aaron Elliott
Aaron Elliott serves as the Chief Executive Officer at Freenome, a position he assumed in April 2025. With nearly two decades of experience in the diagnostics industry, he is responsible for directing the company's strategy and operational execution, focusing on advancing Freenome's early cancer detection platform and guiding the launch of its colorectal cancer screening blood test.
Career Milestones
- Aaron Elliott became CEO of Freenome in April 2025, bringing nearly 20 years of diagnostics industry experience.
- From 2016 to 2021, as CEO of Ambry Genetics, he transformed it into a leading hereditary cancer testing lab, launching tests with high diagnostic yield.
- He led Ambry's $1 billion acquisition by Konica Minolta in 2017.
- Most recently, he served as CEO and President of REALM IDx, Inc.
- His leadership aligns with Freenome's mission to make early cancer detection accessible for everyone.
About Freenome
Freenome, founded in 2014, is a biotechnology company focused on early cancer detection. They develop non-invasive blood tests using a multiomics platform and AI to detect cancer in its earliest, most treatable stages. Freenome aims to make cancer screening accessible and improve patient outcomes.